MCID: ESS001
MIFTS: 59

Essential Tremor

Categories: Genetic diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Essential Tremor

MalaCards integrated aliases for Essential Tremor:

Name: Essential Tremor 12 54 26 55 38 30 56 6 45 15 17 74
Hereditary Essential Tremor 54 26 6
Benign Essential Tremor 12 54 26
Essential Tremor, Susceptibility to 13 6
Familial Tremor 26 74
Benign Essential Tremor Syndrome 77
Tremor, Hereditary Essential, 1 54
Essential Hereditary Tremor 12
Tremor Hereditary Essential 77
Familial Essential Tremor 54
Presenile Tremor Syndrome 54
Shaky Hand Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4990
KEGG 38 H01577
MeSH 45 D020329
SNOMED-CT 69 632009
ICD10 34 G25.0

Summaries for Essential Tremor

NINDS : 55 Tremor is an unintentional, somewhat rhythmic, muscle movement involving to-and-fro movements (oscillations) of one or more parts of the body. Essential tremor (previously called benign essential tremor) is the most common form of abnormal tremor. (In some people, tremor is a symptom of a neurological disorder or appears as a side effect of certain drugs.)  Although it may be mild and nonprogressive in some people, in others the tremor is slowly progressive, starting on one side of the body but eventually affecting both sides. Hand tremor is most common but the head, arms, voice, tongue, legs, and trunk may also be involved. Hand tremor may cause problems with purposeful movements such as eating, writing, sewing, or shaving. Head tremor may be seen as a "yes-yes" or "no-no" motion. Essential tremor may be accompanied by mild gait disturbance. Heightened emotion, stress, fever, physical exhaustion, or low blood sugar may trigger tremors or increase their severity. There may be mild degeneration in the certain parts of the cerebellum in persons with essential tremor.  Onset is most common after age 40, although symptoms can appear at any age. Children of a parent who has essential tremor have up to a 50 percent chance of inheriting the condition. Essential tremor is not associated with any known pathology.

MalaCards based summary : Essential Tremor, also known as hereditary essential tremor, is related to tremor and movement disease, and has symptoms including tremor, action tremor and essential and other specified forms of tremor. An important gene associated with Essential Tremor is ETM2 (Essential Tremor 2), and among its related pathways/superpathways are Neuroscience and Parkinsons Disease Pathway. The drugs Dopamine and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and thalamus, and related phenotype is nervous system.

Disease Ontology : 12 A movement disorder that causes involuntary tremors, especially in the hands. It occurs alone without other neurological signs and symptoms.

Genetics Home Reference : 26 Essential tremor is a movement disorder that causes involuntary, rhythmic shaking (tremor), especially in the hands. It is distinguished from tremor that results from other disorders or known causes, such as Parkinson disease or head trauma. Essential tremor usually occurs alone, without other neurological signs or symptoms. However, some experts think that essential tremor can include additional features, such as mild balance problems.

NIH Rare Diseases : 54 Essential tremor is the most common movement disorder.  It is characterized by involuntary and rhythmic shaking (tremor), especially in the hands, without any other signs or symptoms. It is distinguished from tremor that results from other disorders or known causes, such as tremors seen with Parkinson disease or head trauma. Most cases of essential tremor are hereditary. There are five forms of essential tremor that are based on different genetic causes. Several genes as well as lifestyle and environmental factors likely play a role in a person's risk of developing this complex condition. In mild cases, treatment may not be necessary. In cases where symptoms interfere with daily living, medications may help to relieve symptoms.     

Wikipedia : 77 Essential tremor (ET, also referred to as benign tremor, familial tremor, or idiopathic tremor) is a... more...

Related Diseases for Essential Tremor

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Essential Tremor

Diseases related to Essential Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Related Disease Score Top Affiliating Genes
1 tremor 31.7 DNAJC13 DRD3 FMR1 FUS HTRA2 LRRK2
2 movement disease 31.5 DRD3 FMR1 LRRK2 PRKN SLC6A3 SNCA
3 dementia 30.1 FUS LRRK2 PRKN SLC6A3 SNCA
4 multiple system atrophy 1 30.1 LRRK2 PRKN SLC6A3 SNCA
5 rem sleep behavior disorder 29.8 LRRK2 SLC6A3 SNCA
6 supranuclear palsy, progressive, 1 29.8 LRRK2 PRKN SLC6A3 SNCA
7 parkinson disease, late-onset 29.8 DNAJC13 DRD3 HTRA2 LINGO1 LRRK2 PRKN
8 early-onset parkinson's disease 29.7 LRRK2 PRKN SNCA
9 tremor, hereditary essential, and idiopathic normal pressure hydrocephalus 12.4
10 sensorineural hearing loss-early graying-essential tremor syndrome 12.3
11 tremor, hereditary essential, 1 12.0
12 tremor, hereditary essential, 5 11.8
13 tremor, hereditary essential, 2 11.6
14 tremor, nystagmus, and duodenal ulcer 11.3
15 tremor, hereditary essential, 3 11.3
16 tremor, hereditary essential, 4 11.3
17 mental retardation, autosomal recessive 48 11.3
18 nephronophthisis-like nephropathy 1 11.1
19 primary orthostatic tremor 11.1
20 x-linked dystonia-parkinsonism/lubag 11.1
21 deep brain stimulation for movement disorders 11.1
22 dystonia 10.5
23 restless legs syndrome 10.3
24 cervical dystonia 10.3
25 depression 10.3
26 alzheimer disease 10.2
27 dysautonomia 10.2 DNAJC13 SNCA
28 postencephalitic parkinson disease 10.2 LRRK2 SNCA
29 hereditary late-onset parkinson disease 10.1 DNAJC13 LRRK2 SNCA
30 anxiety 10.1
31 parkinson disease 15, autosomal recessive early-onset 10.1 PRKN SNCA
32 parkinson disease 10 10.1 LRRK2 PRKN SNCA
33 bell's palsy 10.1 HS1BP3 PRKN
34 parkinson disease 3, autosomal dominant 10.1 LRRK2 PRKN SNCA
35 torticollis 10.1
36 aging 10.1
37 body mass index quantitative trait locus 1 10.1
38 charcot-marie-tooth disease 10.1
39 tooth disease 10.1
40 social phobia 10.1
41 benign shuddering attacks 10.1
42 toxic encephalopathy 10.0 SLC1A2 SLC6A3 SNCA
43 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
44 hypogonadotropic hypogonadism 10.0
45 sensorineural hearing loss 10.0
46 sarcoma 10.0
47 pathologic nystagmus 10.0
48 motor neuron disease 9.9 FUS SLC1A2 SNCA
49 striatonigral degeneration 9.9 SLC6A3 SNCA
50 disease of mental health 9.9 DRD3 FMR1 SLC6A3 SNCA

Graphical network of the top 20 diseases related to Essential Tremor:



Diseases related to Essential Tremor

Symptoms & Phenotypes for Essential Tremor

UMLS symptoms related to Essential Tremor:


tremor, action tremor, essential and other specified forms of tremor, senile tremor, physiological tremor

MGI Mouse Phenotypes related to Essential Tremor:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.32 DRD3 FMR1 HTRA2 LINGO1 LRRK2 PRKN

Drugs & Therapeutics for Essential Tremor

Drugs for Essential Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3 62-31-7, 51-61-6 681
2
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
3
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
4
Memantine Approved, Investigational Phase 4 19982-08-2 4054
5
Propranolol Approved, Investigational Phase 4,Not Applicable 525-66-6 4946
6
Iodine Approved, Investigational Phase 4 7553-56-2 807
7
Calcium Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 7440-70-2 271
8 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
9 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Dopamine Agents Phase 4,Phase 3
12 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Acetylcholine Release Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
14 Botulinum Toxins Phase 4,Phase 3,Phase 2,Not Applicable
15 Hormones Phase 4,Phase 2,Not Applicable
16 Psychotropic Drugs Phase 4
17 calcium channel blockers Phase 4,Phase 2,Not Applicable
18 Anti-Anxiety Agents Phase 4
19 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable
20 Calcium, Dietary Phase 4,Phase 2,Not Applicable
21 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Tranquilizing Agents Phase 4
23 Excitatory Amino Acids Phase 4
24 Antiparkinson Agents Phase 4,Phase 3
25 Excitatory Amino Acid Antagonists Phase 4
26 Adrenergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
27 Antihypertensive Agents Phase 4,Not Applicable
28 Anti-Arrhythmia Agents Phase 4,Not Applicable
29 Adrenergic beta-Antagonists Phase 4,Not Applicable
30 Adrenergic Antagonists Phase 4,Not Applicable
31 Vasodilator Agents Phase 4,Not Applicable
32 Pharmaceutical Solutions Phase 4,Phase 2
33 cadexomer iodine Phase 4
34 Calamus Phase 4
35
Cocaine Approved, Illicit Phase 3 50-36-2 446220 5760
36
Topiramate Approved Phase 3 97240-79-4 5284627
37
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
38
Pancrelipase Approved, Investigational Phase 2, Phase 3 53608-75-6
39
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3,Not Applicable 113775-47-6 68602 5311068
40 Botulinum Toxins, Type A Phase 3,Phase 2,Not Applicable
41 abobotulinumtoxinA Phase 3,Phase 2,Not Applicable
42 Neurotransmitter Uptake Inhibitors Phase 3
43 Anesthetics Phase 3,Phase 2,Not Applicable
44 Anesthetics, Local Phase 3,Not Applicable
45 Vasoconstrictor Agents Phase 3
46 Dopamine Uptake Inhibitors Phase 3
47 Hypoglycemic Agents Phase 3
48 Gastrointestinal Agents Phase 2, Phase 3,Not Applicable
49 Immunosuppressive Agents Phase 2, Phase 3
50 Calcineurin Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 159)
# Name Status NCT ID Phase Drugs
1 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
2 A Pilot Clinical Trial Of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
3 Pregabalin (Lyrica) for the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
4 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
5 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
6 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Completed NCT00382967 Phase 4
7 Atlas Predicted DBS Settings in Essential Tremor Active, not recruiting NCT02678429 Phase 4
8 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
9 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor Unknown status NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
10 Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor Unknown status NCT00724906 Phase 3 123 I - ALTROPANE®
11 Novel Therapies for Essential Tremor Completed NCT00018564 Phase 3 treatments for essential tremor
12 A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause. Completed NCT00236496 Phase 3 topiramate
13 Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients Completed NCT00468078 Phase 3 F-18 FPCIT
14 CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients Recruiting NCT03769298 Phase 2, Phase 3 Envarsus XR
15 Pre-lemniscal Radiation Deep Brain Stimulation for ET Terminated NCT00634478 Phase 2, Phase 3
16 Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor Withdrawn NCT01441284 Phase 3 pramipexole;placebo
17 Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation Withdrawn NCT00608231 Phase 2, Phase 3 Dexmedetomidine Hydrochloride Infusion;Normal Saline
18 An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor Unknown status NCT02668146 Phase 2 Perampanel;Placebo
19 Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres? Unknown status NCT02960243 Phase 1, Phase 2
20 Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor Unknown status NCT01945567 Phase 2
21 A Phase 2 RCT Study of CX-8998 for Essential Tremor Completed NCT03101241 Phase 2 CX-8998;Placebo
22 A Pilot Efficacy and Safety Study of ST101 in Essential Tremor Completed NCT01332695 Phase 2 ST101;Placebo
23 A Safety/Efficacy Trial of Zonisamide for Essential Tremor Completed NCT00223743 Phase 2 Zonisamide
24 A Study to Evaluate SAGE-217 in Subjects With Essential Tremor Completed NCT02978781 Phase 2 SAGE-217;Placebo
25 Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor Completed NCT00598078 Phase 2 Sodium Oxybate;Sodium Oxybate
26 Evaluate SAGE-547 in Patients With Essential Tremor Completed NCT02277106 Phase 2 SAGE-547;Placebo
27 A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor Completed NCT00524056 Phase 2 Carisbamate;Placebo
28 Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor Completed NCT00848172 Phase 1, Phase 2 Octanoic Acid;Placebo
29 Efficacy of Levetiracetam in Essential Tremor Completed NCT00620165 Phase 1, Phase 2 levetiracetam;placebo
30 Octanol to Treat Essential Tremor Completed NCT00080366 Phase 2 1-Octanol
31 Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor Completed NCT00102596 Phase 2 1-Octanol
32 Botulinum Toxin A to Treat Arm Tremor Completed NCT02207946 Phase 2 IncobotulinumtoxinA;Placebo
33 Effects of Octanoic Acid for Treatment of Essential Voice Tremor Completed NCT01864525 Phase 1, Phase 2 Octanoic acid;Inactive capsule
34 Trial of Cannabis for Essential Tremor Recruiting NCT03805750 Phase 1, Phase 2 CBD/THC;Placebo oral capsule
35 tSMS in Essential Tremor Recruiting NCT03780426 Phase 2
36 A Clinical Study to Evaluate CAD-1883 in Essential Tremor Recruiting NCT03688685 Phase 2 CAD-1883
37 Kinematic-based BoNT-A Injections for Bilateral ET Active, not recruiting NCT02551848 Phase 2 Botulinum toxin type A
38 Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease Active, not recruiting NCT02427646 Phase 2 IncobotulinumtoxinA
39 Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy Active, not recruiting NCT02668497 Phase 2 Botulinum Toxin Type A
40 T2000 in Essential Tremor - Open Label Continuation Terminated NCT00655278 Phase 2 T2000
41 A Study of T2000 in Essential Tremor Terminated NCT00321087 Phase 2 T2000;T2000;T2000
42 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial Unknown status NCT02558634 Phase 1
43 Octanoic Acid for Essential Tremor Completed NCT01468948 Phase 1 Octanoic Acid
44 ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Completed NCT02037217 Phase 1
45 ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Completed NCT01304758 Phase 1
46 1-Octanol to Treat Essential Tremor Completed NCT00016679 Phase 1 1-Octanol
47 1-Octanol to Treat Essential Tremor Completed NCT00001986 Phase 1 1-Octanol
48 Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders Completed NCT01698450 Phase 1
49 Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation Unknown status NCT02052271 Not Applicable
50 Imaging in the Diagnosis of Parkinson's Disease and Essential Tremor Unknown status NCT01446939

Search NIH Clinical Center for Essential Tremor

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: essential tremor

Genetic Tests for Essential Tremor

Genetic tests related to Essential Tremor:

# Genetic test Affiliating Genes
1 Essential Tremor 30

Anatomical Context for Essential Tremor

MalaCards organs/tissues related to Essential Tremor:

42
Brain, Cerebellum, Thalamus, Tongue, Testes, Cortex, Eye

Publications for Essential Tremor

Articles related to Essential Tremor:

(show top 50) (show all 1860)
# Title Authors Year
1
The Roles of Age and Aging in Essential Tremor: An Epidemiological Perspective. ( 30625472 )
2019
2
Essential Tremor is not Only a Movement Disorder; Its Relationship with Sleep and Anxiety. ( 30911232 )
2019
3
Dementia in Essential Tremor: A Visual Record. ( 30867979 )
2019
4
Cortical dynamics within and between parietal and motor cortex in essential tremor. ( 30345712 )
2019
5
White matter differences between essential tremor and Parkinson disease. ( 30504432 )
2019
6
A Quantitative Study of Empty Baskets in Essential Tremor and Other Motor Neurodegenerative Diseases. ( 30590599 )
2019
7
Reclassifying essential tremor: Implications for the future of past research. ( 30653249 )
2019
8
From beta-blockers to Parkinson's disease in respect of essential tremor. ( 30653724 )
2019
9
Reply to: From beta-blockers to Parkinson's disease in respect of essential tremor. ( 30653730 )
2019
10
Essential tremor severity and anatomical changes in brain areas controlling movement sequencing. ( 30656186 )
2019
11
Repeat magnetic resonance imaging-guided focused ultrasound thalamotomy for recurrent essential tremor: case report and review of MRI findings. ( 30684946 )
2019
12
Phenotypic Variability of Essential Tremor Based on the Age at Onset. ( 30688180 )
2019
13
An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor. ( 30701655 )
2019
14
Essential Tremor. ( 30704686 )
2019
15
Yoga led by a physical therapist for individuals with Essential Tremor: An explorative pilot study. ( 30712723 )
2019
16
Peripheral BDNF/TrkB protein expression is decreased in Parkinson's disease but not in Essential tremor. ( 30723034 )
2019
17
Four-year follow-up results of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. ( 30759322 )
2019
18
Shorter pulse width reduces gait disturbances following deep brain stimulation for essential tremor. ( 30765417 )
2019
19
Feasibility of Staged Bilateral Radiofrequency Vim Thalamotomy for Bilateral Essential Tremor. ( 30771542 )
2019
20
Correlation between fractional anisotropy changes in the targeted ventral intermediate nucleus and clinical outcome after transcranial MR-guided focused ultrasound thalamotomy for essential tremor: results of a pilot study. ( 30771772 )
2019
21
Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in essential tremor. ( 30785244 )
2019
22
Long-term efficacy of deep brain stimulation for essential tremor: An observer-blinded study. ( 30787161 )
2019
23
Personalized Bilateral Upper Limb Essential Tremor Therapy with Botulinum Toxin Using Kinematics. ( 30791440 )
2019
24
Unilateral Thalamic Deep Brain Stimulation vs. Focused Ultrasound Thalamotomy for Essential Tremor. ( 30794976 )
2019
25
Combined Visualization of Nigrosome-1 and Neuromelanin in the Substantia Nigra Using 3T MRI for the Differential Diagnosis of Essential Tremor and de novo Parkinson's Disease. ( 30809189 )
2019
26
Adjustment Distress to Successful Deep Brain Stimulation for Essential Tremor: Unexpected Intrapsychic Conflict in Response to Symptom Control. ( 30827494 )
2019
27
Decoding voluntary movements and postural tremor based on thalamic LFPs as a basis for closed-loop stimulation for essential tremor. ( 30827864 )
2019
28
Gait worsening and the microlesion effect following deep brain stimulation for essential tremor. ( 30846538 )
2019
29
Cognitive safety after unilateral magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. ( 30850471 )
2019
30
Enfeeblement in Essential Tremor: Development and Validation of a New Psychometric Measure. ( 30857453 )
2019
31
Microstructural changes of the dentato-rubro-thalamic tract after transcranial MR guided focused ultrasound ablation of the posteroventral VIM in essential tremor. ( 30865338 )
2019
32
An Unusual Case of Essential Tremor Deep Brain Stimulation: Where is the Lead? ( 30867977 )
2019
33
Eye movement abnormalities in essential tremor versus tremor dominant Parkinson's disease. ( 30875535 )
2019
34
Mind the gaps: What we don't know about cognitive impairment in essential tremor. ( 30876840 )
2019
35
Focused Ultrasound Thalamotomy for Essential Tremor in the Setting of a Ventricular Shunt: Technical Report. ( 30888021 )
2019
36
Abnormal hippocampal subfields are associated with cognitive impairment in Essential Tremor. ( 30888510 )
2019
37
Prevalence of Essential Tremor in the Faroe Islands: A Population-Based Study. ( 30889566 )
2019
38
Adapted Feeding Utensils for People With Parkinson's-Related or Essential Tremor. ( 30915973 )
2019
39
Caffeine Consumption in First-Degree Relatives of Essential Tremor Cases: Evidence of Dietary Modification Before Disease Onset. ( 29953981 )
2018
40
Deep Brain Stimulation Management of Essential Tremor with Dystonic Features. ( 29971197 )
2018
41
Objective predictors of 'early tolerance' to ventral intermediate nucleus of thalamus deep brain stimulation in essential tremor patients. ( 29908405 )
2018
42
Unilateral Left Deep Brain Stimulation of the Caudal Zona Incerta Is Equally Effective on Voice Tremor as Bilateral Stimulation: Evidence from 7 Patients with Essential Tremor. ( 29975951 )
2018
43
The effects of Thalamic Deep Brain Stimulation on speech dynamics in patients with Essential Tremor: An articulographic study. ( 29360867 )
2018
44
Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases. ( 28298022 )
2018
45
White matter measures correlate with essential tremor severity-A pilot diffusion tensor imaging study. ( 29964316 )
2018
46
Clinical response to Vim's thalamic stereotactic radiosurgery for essential tremor is associated with distinctive functional connectivity patterns. ( 29335882 )
2018
47
Comparative Burden of Subclinical Tremor in a Cohort of Normal Individuals Stratified by Familial Risk for Essential Tremor. ( 29339654 )
2018
48
A method for pre-operative single-subject thalamic segmentation based on probabilistic tractography for essential tremor deep brain stimulation. ( 29307012 )
2018
49
Essential tremor: "Plus" or "Minus". Perhaps now is the time to adopt the term "the essential tremors". ( 29937098 )
2018
50
Hand Tremor Questionnaire: A Useful Screening Tool for Differentiating Patients with Hand Tremor between Parkinson's Disease and Essential Tremor. ( 29971978 )
2018

Variations for Essential Tremor

ClinVar genetic disease variations for Essential Tremor:

6 (show all 44)
# Gene Variation Type Significance SNP ID Assembly Location
1 DRD3 NM_000796.5(DRD3): c.25G> A (p.Gly9Ser) single nucleotide variant Likely benign rs6280 GRCh37 Chromosome 3, 113890815: 113890815
2 DRD3 NM_000796.5(DRD3): c.25G> A (p.Gly9Ser) single nucleotide variant Likely benign rs6280 GRCh38 Chromosome 3, 114171968: 114171968
3 DNAJC13 NM_015268.3(DNAJC13): c.2564A> G (p.Asn855Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs387907571 GRCh37 Chromosome 3, 132196839: 132196839
4 DNAJC13 NM_015268.3(DNAJC13): c.2564A> G (p.Asn855Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs387907571 GRCh38 Chromosome 3, 132477995: 132477995
5 DRD3 NM_000796.5(DRD3): c.691T> A (p.Cys231Ser) single nucleotide variant Uncertain significance rs150042478 GRCh38 Chromosome 3, 114139532: 114139532
6 DRD3 NM_000796.5(DRD3): c.691T> A (p.Cys231Ser) single nucleotide variant Uncertain significance rs150042478 GRCh37 Chromosome 3, 113858379: 113858379
7 DRD3 NM_000796.5(DRD3): c.302T> G (p.Ile101Ser) single nucleotide variant Uncertain significance rs886057789 GRCh38 Chromosome 3, 114159836: 114159836
8 DRD3 NM_000796.5(DRD3): c.302T> G (p.Ile101Ser) single nucleotide variant Uncertain significance rs886057789 GRCh37 Chromosome 3, 113878683: 113878683
9 DRD3 NM_000796.5(DRD3): c.821G> A (p.Gly274Glu) single nucleotide variant Uncertain significance rs200825904 GRCh38 Chromosome 3, 114131303: 114131303
10 DRD3 NM_000796.5(DRD3): c.821G> A (p.Gly274Glu) single nucleotide variant Uncertain significance rs200825904 GRCh37 Chromosome 3, 113850150: 113850150
11 DRD3 NM_000796.5(DRD3): c.-105G> A single nucleotide variant Likely benign rs36211802 GRCh38 Chromosome 3, 114178726: 114178726
12 DRD3 NM_000796.5(DRD3): c.-105G> A single nucleotide variant Likely benign rs36211802 GRCh37 Chromosome 3, 113897573: 113897573
13 DRD3 NM_000796.5(DRD3): c.-252C> T single nucleotide variant Likely benign rs36211803 GRCh38 Chromosome 3, 114178873: 114178873
14 DRD3 NM_000796.5(DRD3): c.-252C> T single nucleotide variant Likely benign rs36211803 GRCh37 Chromosome 3, 113897720: 113897720
15 DRD3 NM_000796.5(DRD3): c.-281A> G single nucleotide variant Uncertain significance rs199852439 GRCh38 Chromosome 3, 114178902: 114178902
16 DRD3 NM_000796.5(DRD3): c.-281A> G single nucleotide variant Uncertain significance rs199852439 GRCh37 Chromosome 3, 113897749: 113897749
17 DRD3 NM_000796.5(DRD3): c.-286A> C single nucleotide variant Likely benign rs190248679 GRCh38 Chromosome 3, 114178907: 114178907
18 DRD3 NM_000796.5(DRD3): c.-286A> C single nucleotide variant Likely benign rs190248679 GRCh37 Chromosome 3, 113897754: 113897754
19 DRD3 NM_000796.5(DRD3): c.270+14A> G single nucleotide variant Uncertain significance rs75091114 GRCh38 Chromosome 3, 114171709: 114171709
20 DRD3 NM_000796.5(DRD3): c.270+14A> G single nucleotide variant Uncertain significance rs75091114 GRCh37 Chromosome 3, 113890556: 113890556
21 DRD3 NM_000796.5(DRD3): c.-114A> G single nucleotide variant Uncertain significance rs886057790 GRCh38 Chromosome 3, 114178735: 114178735
22 DRD3 NM_000796.5(DRD3): c.-114A> G single nucleotide variant Uncertain significance rs886057790 GRCh37 Chromosome 3, 113897582: 113897582
23 DRD3 NM_000796.5(DRD3): c.-153T> G single nucleotide variant Uncertain significance rs200345655 GRCh38 Chromosome 3, 114178774: 114178774
24 DRD3 NM_000796.5(DRD3): c.-153T> G single nucleotide variant Uncertain significance rs200345655 GRCh37 Chromosome 3, 113897621: 113897621
25 DRD3 NM_000796.5(DRD3): c.-318C> T single nucleotide variant Uncertain significance rs201561838 GRCh38 Chromosome 3, 114178939: 114178939
26 DRD3 NM_000796.5(DRD3): c.-318C> T single nucleotide variant Uncertain significance rs201561838 GRCh37 Chromosome 3, 113897786: 113897786
27 DRD3 NM_000796.5(DRD3): c.1151C> A (p.Thr384Asn) single nucleotide variant Uncertain significance rs886057788 GRCh38 Chromosome 3, 114128768: 114128768
28 DRD3 NM_000796.5(DRD3): c.1151C> A (p.Thr384Asn) single nucleotide variant Uncertain significance rs886057788 GRCh37 Chromosome 3, 113847615: 113847615
29 DRD3 NM_000796.5(DRD3): c.1077C> T (p.His359=) single nucleotide variant Uncertain significance rs3732791 GRCh38 Chromosome 3, 114128842: 114128842
30 DRD3 NM_000796.5(DRD3): c.1077C> T (p.His359=) single nucleotide variant Uncertain significance rs3732791 GRCh37 Chromosome 3, 113847689: 113847689
31 DRD3 NM_000796.5(DRD3): c.987A> G (p.Gln329=) single nucleotide variant Likely benign rs61735073 GRCh38 Chromosome 3, 114131137: 114131137
32 DRD3 NM_000796.5(DRD3): c.987A> G (p.Gln329=) single nucleotide variant Likely benign rs61735073 GRCh37 Chromosome 3, 113849984: 113849984
33 DRD3 NM_000796.5(DRD3): c.720A= (p.Gln240=) single nucleotide variant Likely benign rs2251177 GRCh38 Chromosome 3, 114139503: 114139503
34 DRD3 NM_000796.5(DRD3): c.720A= (p.Gln240=) single nucleotide variant Likely benign rs2251177 GRCh37 Chromosome 3, 113858350: 113858350
35 DRD3 NM_000796.5(DRD3): c.383+7C> T single nucleotide variant Uncertain significance rs200206712 GRCh38 Chromosome 3, 114159748: 114159748
36 DRD3 NM_000796.5(DRD3): c.383+7C> T single nucleotide variant Uncertain significance rs200206712 GRCh37 Chromosome 3, 113878595: 113878595
37 DRD3 NM_000796.5(DRD3): c.51A> G (p.Ala17=) single nucleotide variant Likely benign rs3732783 GRCh38 Chromosome 3, 114171942: 114171942
38 DRD3 NM_000796.5(DRD3): c.51A> G (p.Ala17=) single nucleotide variant Likely benign rs3732783 GRCh37 Chromosome 3, 113890789: 113890789
39 DRD3 NM_000796.5(DRD3): c.-38A> C single nucleotide variant Uncertain significance rs201872343 GRCh38 Chromosome 3, 114178659: 114178659
40 DRD3 NM_000796.5(DRD3): c.-38A> C single nucleotide variant Uncertain significance rs201872343 GRCh37 Chromosome 3, 113897506: 113897506
41 DRD3 NM_000796.5(DRD3): c.-333G> A single nucleotide variant Likely benign rs36212175 GRCh38 Chromosome 3, 114178954: 114178954
42 DRD3 NM_000796.5(DRD3): c.-333G> A single nucleotide variant Likely benign rs36212175 GRCh37 Chromosome 3, 113897801: 113897801
43 DRD3 NM_000796.5(DRD3): c.-388T> A single nucleotide variant Uncertain significance rs886057791 GRCh38 Chromosome 3, 114179009: 114179009
44 DRD3 NM_000796.5(DRD3): c.-388T> A single nucleotide variant Uncertain significance rs886057791 GRCh37 Chromosome 3, 113897856: 113897856

Expression for Essential Tremor

Search GEO for disease gene expression data for Essential Tremor.

Pathways for Essential Tremor

Pathways related to Essential Tremor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 FMR1 LINGO1 LRRK2 PRKN SLC1A2 SNCA
2 10.95 HTRA2 LRRK2 PRKN SLC6A3 SNCA
3 10.84 PRKN SLC6A3 SNCA

GO Terms for Essential Tremor

Cellular components related to Essential Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth cone GO:0030426 9.63 FMR1 LRRK2 SNCA
2 perikaryon GO:0043204 9.61 FMR1 FUS LRRK2
3 presynapse GO:0098793 9.58 FMR1 PRKN SNCA
4 neuronal cell body GO:0043025 9.55 FMR1 FUS LRRK2 SLC6A3 SNCA
5 postsynapse GO:0098794 9.5 FMR1 LRRK2 SNCA
6 inclusion body GO:0016234 9.37 LRRK2 SNCA
7 axon GO:0030424 9.35 FMR1 LRRK2 SLC1A2 SLC6A3 SNCA
8 dopaminergic synapse GO:0098691 9.26 DRD3 SLC6A3
9 neuron projection GO:0043005 9.1 FMR1 GABRR3 LRRK2 PRKN SLC6A3 TENM4

Biological processes related to Essential Tremor according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.92 DRD3 SLC1A2 SLC6A3 SNCA
2 mitochondrion organization GO:0007005 9.76 HTRA2 LRRK2 PRKN
3 locomotory behavior GO:0007626 9.75 DRD3 PRKN SLC6A3
4 cellular response to oxidative stress GO:0034599 9.74 HTRA2 LRRK2 SNCA
5 negative regulation of protein phosphorylation GO:0001933 9.71 LRRK2 PRKN SNCA
6 adult locomotory behavior GO:0008344 9.67 HTRA2 PRKN SNCA
7 regulation of reactive oxygen species metabolic process GO:2000377 9.64 PRKN SNCA
8 behavioral response to cocaine GO:0048148 9.63 DRD3 SNCA
9 regulation of neuron death GO:1901214 9.63 LRRK2 SNCA
10 cellular protein catabolic process GO:0044257 9.62 HTRA2 PRKN
11 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.61 LRRK2 PRKN
12 positive regulation of proteasomal protein catabolic process GO:1901800 9.61 FMR1 PRKN
13 response to cocaine GO:0042220 9.61 DRD3 SLC6A3 SNCA
14 prepulse inhibition GO:0060134 9.6 DRD3 SLC6A3
15 cellular response to dopamine GO:1903351 9.59 LRRK2 PRKN
16 dopamine biosynthetic process GO:0042416 9.56 SLC6A3 SNCA
17 regulation of dopamine metabolic process GO:0042053 9.55 PRKN SLC6A3
18 regulation of dopamine secretion GO:0014059 9.54 DRD3 PRKN SNCA
19 cellular response to manganese ion GO:0071287 9.52 LRRK2 PRKN
20 protein localization to mitochondrion GO:0070585 9.51 LRRK2 PRKN
21 regulation of neurotransmitter secretion GO:0046928 9.5 FMR1 PRKN SNCA
22 dopamine uptake involved in synaptic transmission GO:0051583 9.48 PRKN SNCA
23 positive regulation of dopamine receptor signaling pathway GO:0060161 9.46 DRD3 LRRK2
24 synaptic transmission, dopaminergic GO:0001963 9.43 DRD3 PRKN SNCA
25 regulation of synaptic vesicle transport GO:1902803 9.4 LRRK2 PRKN
26 dopamine metabolic process GO:0042417 9.33 DRD3 PRKN SNCA
27 negative regulation of neuron death GO:1901215 9.26 HTRA2 LRRK2 PRKN SNCA
28 regulation of locomotion GO:0040012 8.8 DRD3 LRRK2 SNCA

Molecular functions related to Essential Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 FMR1 FUS HTRA2 LRRK2 PRKN SNCA
2 dynein complex binding GO:0070840 9.26 FMR1 SNCA
3 phospholipase binding GO:0043274 8.96 PRKN SNCA
4 dopamine binding GO:0035240 8.62 DRD3 SLC6A3

Sources for Essential Tremor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....